

## **PUBLICATIONS GAVIN MARX**

Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, Piyushkumar A Mundra, Calan Spielman, Karen Briscoe, Howard Gurney, Girish Mallesara, **Gavin Marx**, Martin R Stockler, Robert G Parton, Andrew J Hoy, Roger J Daly, Peter J Meikle, Lisa G Horvath. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. *Int Journal of Cancer* Aug 2017

J N Pulvers, **G Marx**. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. *Asia-Pacific Journal of Clinical Oncology*, 2017

Hui-Ming Lin<sup>1,2</sup>, Kate L Mahon<sup>1,2,3,4</sup>, Calan Spielman<sup>1</sup>, Howard Gurney<sup>5,6</sup>, Girish Mallesara<sup>6,7</sup>, Martin R Stockler<sup>3,4,6,8,9</sup>, Patricia Bastick<sup>6,10</sup>, Karen Briscoe<sup>6,11</sup>, **Gavin Marx<sup>6,12</sup>**, Alexander Swarbrick<sup>1,2</sup> and Lisa G Horvath. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. *British Journal of Cancer* (2017) 116, 1002–1011. doi:10.1038/bjc.2017.50 [www.bjcancer.com](http://www.bjcancer.com) March 2017

Thomas CL<sup>1,2</sup>, Arasaratnam M<sup>3</sup>, Carlos G<sup>1,2,4</sup>, Parasyn A<sup>5</sup>, Baumgart KW<sup>6</sup>, Fernandez-Penas P<sup>1,2,4</sup>, **Marx G<sup>2,3</sup>**. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. *Australas J Dermatol*. 2017 Feb; 58(1):69-70.

A. R. T. Bergin, E. Hovey, A. Lloyd, G. **Marx**, P. Parente, T. Rapke, P. de Souza. Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. *Support Care Cancer* September 2017

Bergin A, Hovey E, Lloyd A, **Marx G**, Parente P, Rapke T, De Souza P. Docetaxel-related Fatigue in Metastatic Prostate Cancer: A Descriptive Analysis. *Asia-Pacific Journal of Clinical Oncology* 12:52-52 August 2016

Li B, Barnes T, Chan D, Naidoo J, Lee A, Khasraw M, **Marx G**, Kris M, Clarke S, Drilon A, Pavlakis N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer*, 102, 21-27 2016

Roger von Moos, Jean Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, **Gavin Marx**, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. *Supportive Care in Cancer*. March 2016

Kao S, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, **Marx G**, Cullen M, Kerestes Z, Pavlakis N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Lung cancer (Amsterdam, Netherlands)*. 75(2), 248-54. 2012

Tebbutt N, Murphy F, Zannino D, Wilson K, Cummins M, Abdi E, Strickland A, Lowenthal R, **Marx G**, Karapetis C, Shannon J, Goldstein D, Nayagam S, Blum R, Chantrill L, Simes R, Price T, Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. *Annals of Oncology* 2011

Christos S Karapetis, Kerry A Cheong, Desmond Yip, Andrew H Strickland, Christopher Steer, **Gavin Marx**, Sonia Yip, Kathryn Chrystal, Peter G Harper. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced oesophagogastric carcinomas. *Asia-Pacific Journal of Clinical Oncology*. [Volume 6, Issue 4](#), pages 298–305, December 2010

Diana Adams and **Gavin Marx**. Daily Life As An Australian Medical Oncologist. *Journal of Oncology Practice*, Vol 6, No 3 (May), 2010: pp. 146-148

C B Steer, **G M Marx**, N Singhal, M McJannett, D Goldstein, R Prowse. Cancer in older people: a tale of two disciplines *Internal Medicine Journal*. Volume 39, Issue 11, Date: November 2009, 39(11) Pages: 771-775

M Khasraw<sup>1</sup>, N Pavlakis<sup>1</sup>, S McCowatt<sup>1,2</sup>, C Underhill<sup>3</sup>, S Begbie<sup>4</sup>, P de Souza<sup>5</sup>, A Boyce<sup>6</sup>, F Parnis<sup>7</sup>, V Lim<sup>1</sup>, R Harvie<sup>1</sup>, and **G Marx**. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate- Resistant Prostate Cancer. *Annals of Oncology*, November 2009

Liangli Zhao<sup>1</sup>, Brian Y Lee<sup>1</sup>, David A Brown<sup>3</sup>, Mark P Molloy<sup>4</sup>, **Gavin M Marx**<sup>5</sup>, Nick Pavlakis<sup>5</sup>, Michael J Boyer<sup>6</sup>, Martin R Stockler<sup>6</sup>, Warren Kaplan<sup>2</sup>, Samuel N Breit<sup>3</sup>, Robert L Sutherland<sup>1</sup>, Susan M Henshall<sup>1</sup> and Lisa G Horvath Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. *Cancer Research* 69, 7696, October 1, 2009

Pavlakis N, **Marx G**, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047

Elizabeth Hovey<sup>1</sup>, **Gavin Marx**<sup>2</sup>, Andrew Kneebone<sup>3</sup>, Manish Patel<sup>4</sup> and Jeremy Shapiro An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. Asia Pacific Journal of Oncology and Haematology 2009